This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| DEA National Prescription Drug Take Back Day | |
|---|---|
| Name | DEA National Prescription Drug Take Back Day |
| Status | Active |
| Genre | Public health initiative |
| Dates | Semiannual (typically April and October) |
| Location | Nationwide (United States) |
| Organizer | Drug Enforcement Administration |
| First | 2010 |
DEA National Prescription Drug Take Back Day DEA National Prescription Drug Take Back Day is a semiannual public initiative that organizes temporary collection events for unused and expired prescription medications across the United States. Initiated by the Drug Enforcement Administration in cooperation with federal, state, and local partners, the events involve law enforcement agencies, health departments, and community organizations to provide secure, anonymous disposal. The initiative aims to reduce medication diversion, prevent accidental poisonings, and support public safety and health objectives.
DEA National Prescription Drug Take Back Day convenes coordinated collection efforts that typically occur in April and October, mobilizing partners including the Drug Enforcement Administration, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, and thousands of local law enforcement agencies such as the Federal Bureau of Investigation-partnered task forces. Events are held at sites ranging from municipal police department headquarters to community centers affiliated with organizations like the American Red Cross and Rotary International. The program interfaces with federal statutes such as the Controlled Substances Act when addressing the handling and destruction of collected pharmaceuticals.
The program was launched in 2010 following rising attention to prescription drug misuse highlighted in reports from agencies including the Centers for Disease Control and Prevention and the National Institute on Drug Abuse. Early milestones involved collaboration with the Drug Free America Foundation and state-level actors like the California Department of Public Health. Over subsequent years, partnerships expanded to include municipal actors such as the New York City Police Department and nonprofit stakeholders like Partnership to End Addiction. High-profile policy contexts affecting the initiative have included actions by the United States Congress on opioid legislation and presidential administrations addressing the opioid epidemic.
The primary objectives are to reduce diversion of prescription drugs to illicit markets, prevent accidental ingestion and poisonings, and support safe disposal practices consistent with guidance from the Environmental Protection Agency. The initiative aligns with public health strategies promoted by the World Health Organization and addiction treatment frameworks advanced by entities such as Johns Hopkins Bloomberg School of Public Health and Mayo Clinic. Secondary aims include raising public awareness through outreach with organizations like the American Medical Association and state health departments such as the Massachusetts Department of Public Health.
Participation spans federal agencies, state attorneys general offices such as the Office of the Attorney General (New York), municipal police forces including the Los Angeles Police Department, tribal authorities like the Navajo Nation, and nonprofit partners such as Shatterproof and the American Pharmacists Association. Corporate and academic participants have included pharmacy chains represented by CVS Health and Walgreens Boots Alliance, and research partners such as Harvard Medical School and the University of California San Francisco. Media partners and advocacy groups including National Public Radio and the Drug Policy Alliance have amplified outreach messages.
Collection events are organized as temporary drop-off sites at locations including police station parking lots, municipal buildings, and community organizations such as YMCA branches. Participants can surrender controlled substances and non-controlled medications; sharps and needles are typically excluded per policies aligned with Occupational Safety and Health Administration guidelines. Collected pharmaceuticals are cataloged and transported under chain-of-custody procedures often involving licensed contractors compliant with the Resource Conservation and Recovery Act and local waste management authorities like Waste Management, Inc. Final destruction commonly occurs via high-heat incineration at facilities regulated by the Environmental Protection Agency or through reverse distributor programs overseen by the Food and Drug Administration.
Since inception, cumulative collection totals announced by the Drug Enforcement Administration have represented tens of thousands of pounds of medication removed from circulation, with specific Take Back Days reporting multi-ton hauls collected from thousands of sites nationwide. Analyses by researchers at institutions such as University of Michigan and Columbia University Mailman School of Public Health have examined correlations between collection volumes and local indicators of prescription opioid misuse tracked by the National Institute on Drug Abuse. Policy evaluations by the Congressional Research Service and reporting by The New York Times and The Washington Post have documented shifts in community disposal behaviors and episodic reductions in household stockpiles of unused medications.
Critiques have arisen regarding the program's episodic nature versus the need for permanent disposal infrastructure advocated by groups such as the Drug Policy Alliance and policy analysts at the Brookings Institution. Environmental concerns about incineration emissions have been raised by Sierra Club and Natural Resources Defense Council, prompting debates over alternative destruction technologies supported by researchers at the National Renewable Energy Laboratory. Civil liberties organizations including the American Civil Liberties Union have occasionally scrutinized law enforcement presence at drop-off sites. Fiscal analyses by the Government Accountability Office and oversight discussions in the United States Congress have questioned sustainability, funding levels, and integration with broader opioid epidemic response strategies.
Category:Drug policy in the United States